—
Summary‘Fragile X Syndrome - Pipeline Review, H2 2016’, provides an overview of the Fragile X Syndrome pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects.
Request a sample report @ https://www.wiseguyreports.com/sample-request/693298-fragile-x-syndrome-pipeline-review-h2-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Fragile X Syndrome
- The report reviews pipeline therapeutics for Fragile X Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Fragile X Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Fragile X Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Fragile X Syndrome
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/693298-fragile-x-syndrome-pipeline-review-h2-2016
Key points in table of content
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Fragile X Syndrome Overview 9
Therapeutics Development 10
Pipeline Products for Fragile X Syndrome - Overview 10
Pipeline Products for Fragile X Syndrome - Comparative Analysis 11
Fragile X Syndrome - Therapeutics under Development by Companies 12
Fragile X Syndrome - Therapeutics under Investigation by Universities/Institutes 14
Fragile X Syndrome - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Fragile X Syndrome - Products under Development by Companies 18
Fragile X Syndrome - Products under Investigation by Universities/Institutes 20
Fragile X Syndrome - Companies Involved in Therapeutics Development 21
Aelis Farma SAS 21
Alcobra Ltd 22
AMO Pharma Limited 23
Anavex Life Sciences Corp. 24
Confluence Pharmaceuticals LLC 25
DRI Biosciences Corporation 26
Eli Lilly and Company 27
GlaxoSmithKline Plc 28
GW Pharmaceuticals Plc 29
Kareus Therapeutics, SA 30
Marinus Pharmaceuticals, Inc. 31
Neuren Pharmaceuticals Limited 32
Neuron Biopharma SA 33
Ovid Therapeutics Inc. 34
Sage Therapeutics, Inc. 35
Zynerba Pharmaceuticals, Inc. 36
Fragile X Syndrome - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
acamprosate calcium - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=693298
Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WiseGuy Research Consultant Pvt Ltd
Address: WISE GUY RESEARCH CONSULTANTS PVT LTD Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India Ph: +91 841 198 5042 info@wiseguyreports.com
Phone: +1-646-845-9349 (US) +44 208 133 9349 (UK)t
Website: https://www.wiseguyreports.com
Release ID: 140104
Google
RSS